Intravitreal bevacizumab for choroidal neovascularization associated with Best's disease
| Autor: | J. Rigo Quera, G. Arcos-Algaba, Vicente Martinez-Castillo, C. Macià Badia, L. Velez-Escola, Daniel Velazquez-Villoria, José García-Arumí |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Abstract case
medicine.medical_specialty Best's disease Visual acuity genetic structures medicine.diagnostic_test Bevacizumab business.industry General Medicine Fluorescein angiography eye diseases Choroidal neovascularization Ophthalmology medicine Effective treatment sense organs Intravitreal bevacizumab medicine.symptom business medicine.drug |
| Zdroj: | Archivos de la Sociedad Española de Oftalmología (English Edition). 89:405-407 |
| ISSN: | 2173-5794 |
| DOI: | 10.1016/j.oftale.2014.09.001 |
| Popis: | Case report A 27-year-old woman presented with loss of vision in the right eye (20/200). Ophthalmoscopic examination showed intraretinal hemorrhage in the macular region with neurosensory detachment in the right eye, and viteliform deposit in the left eye. Fluorescein angiography and the electrooculogram confirmed the diagnosis of choroidal neovascularization associated with Best's disease. Four weeks after a single bevacizumab intravitreal injection, visual acuity was restored (20/25) and remained stable after a 12 month follow-up. Discussion Intravitreal bevacizumab appears to be an effective treatment for choroidal neovascularization associated to Best's disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect